CEL-SCI Corp (CVM) - Total Assets
Based on the latest financial reports, CEL-SCI Corp (CVM) holds total assets worth $22.89 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CEL-SCI Corp - Total Assets Trend (1986–2025)
This chart illustrates how CEL-SCI Corp's total assets have evolved over time, based on quarterly financial data. Also see CVM market cap overview for the company's overall valuation and market capitalisation.
CEL-SCI Corp - Asset Composition Analysis
Current Asset Composition (September 2025)
CEL-SCI Corp's total assets of $22.89 Million consist of 41.2% current assets and 58.8% non-current assets. Review CVM total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $10.95 Million | 38.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $303.28K | 1.1% |
| Property, Plant & Equipment | $12.90 Million | 45.8% |
| Intangible Assets | $119.86K | 0.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1986–2025)
This chart illustrates how CEL-SCI Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CVM stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CEL-SCI Corp's current assets represent 41.2% of total assets in 2025, a decrease from 66.7% in 1986.
- Cash Position: Cash and equivalents constituted 38.9% of total assets in 2025, up from 33.3% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1986.
- Asset Diversification: The largest asset category is property, plant & equipment at 45.8% of total assets.
CEL-SCI Corp Competitors by Total Assets
Key competitors of CEL-SCI Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
CEL-SCI Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 1.07 | 3.41 |
| Quick Ratio | 1.35 | 0.91 | 3.16 |
| Cash Ratio | 1.25 | 0.84 | 0.00 |
| Working Capital | $1.99 Million | $378.23K | $14.04 Million |
CEL-SCI Corp - Advanced Valuation Insights
This section examines the relationship between CEL-SCI Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | $28.16 Million |
| Market Capitalization | $12.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values CEL-SCI Corp's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CEL-SCI Corp's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CEL-SCI Corp (1986–2025)
The table below shows the annual total assets of CEL-SCI Corp from 1986 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $28.16 Million | +4.31% |
| 2024-09-30 | $26.99 Million | -11.58% |
| 2023-09-30 | $30.53 Million | -39.58% |
| 2022-09-30 | $50.52 Million | -33.41% |
| 2021-09-30 | $75.87 Million | +87.16% |
| 2020-09-30 | $40.54 Million | +46.75% |
| 2019-09-30 | $27.62 Million | -6.64% |
| 2018-09-30 | $29.59 Million | +29.06% |
| 2017-09-30 | $22.92 Million | +97.65% |
| 2016-09-30 | $11.60 Million | -24.92% |
| 2015-09-30 | $15.45 Million | -19.67% |
| 2014-09-30 | $19.23 Million | +77.43% |
| 2013-09-30 | $10.84 Million | -32.54% |
| 2012-09-30 | $16.07 Million | -13.73% |
| 2011-09-30 | $18.63 Million | -50.73% |
| 2010-09-30 | $37.80 Million | -17.86% |
| 2009-09-30 | $46.03 Million | +213.46% |
| 2008-09-30 | $14.68 Million | -29.17% |
| 2007-09-30 | $20.73 Million | +114.75% |
| 2006-09-30 | $9.65 Million | +212.17% |
| 2005-09-30 | $3.09 Million | -43.92% |
| 2004-09-30 | $5.51 Million | +89.14% |
| 2003-09-30 | $2.92 Million | -22.70% |
| 2002-09-30 | $3.77 Million | -16.36% |
| 2001-09-30 | $4.51 Million | -67.35% |
| 2000-09-30 | $13.81 Million | +81.70% |
| 1999-09-30 | $7.60 Million | -47.22% |
| 1998-09-30 | $14.40 Million | +128.57% |
| 1997-09-30 | $6.30 Million | -47.06% |
| 1996-09-30 | $11.90 Million | +85.94% |
| 1995-09-30 | $6.40 Million | -20.99% |
| 1994-09-30 | $8.10 Million | -30.17% |
| 1993-09-30 | $11.60 Million | -15.94% |
| 1992-09-30 | $13.80 Million | +762.50% |
| 1991-09-30 | $1.60 Million | +220.00% |
| 1990-09-30 | $500.00K | 0.00% |
| 1989-09-30 | $500.00K | -16.67% |
| 1988-09-30 | $600.00K | -14.29% |
| 1987-09-30 | $700.00K | +133.33% |
| 1986-09-30 | $300.00K | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more